BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 19808269)

  • 1. Osteopontin, a new prognostic biomarker in patients with chronic heart failure.
    Rosenberg M; Zugck C; Nelles M; Juenger C; Frank D; Remppis A; Giannitsis E; Katus HA; Frey N
    Circ Heart Fail; 2008 May; 1(1):43-9. PubMed ID: 19808269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure.
    Manzano-Fernández S; Boronat-Garcia M; Albaladejo-Otón MD; Pastor P; Garrido IP; Pastor-Pérez FJ; Martínez-Hernández P; Valdés M; Pascual-Figal DA
    Am J Cardiol; 2009 Jun; 103(12):1753-9. PubMed ID: 19539088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients.
    Niizeki T; Takeishi Y; Arimoto T; Takabatake N; Nozaki N; Hirono O; Watanabe T; Nitobe J; Harada M; Suzuki S; Koyama Y; Kitahara T; Sasaki T; Kubota I
    J Card Fail; 2007 Mar; 13(2):120-7. PubMed ID: 17395052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure.
    Kempf T; von Haehling S; Peter T; Allhoff T; Cicoira M; Doehner W; Ponikowski P; Filippatos GS; Rozentryt P; Drexler H; Anker SD; Wollert KC
    J Am Coll Cardiol; 2007 Sep; 50(11):1054-60. PubMed ID: 17825714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and prognostic significance of elevated gamma-glutamyltransferase in chronic heart failure.
    Poelzl G; Eberl C; Achrainer H; Doerler J; Pachinger O; Frick M; Ulmer H
    Circ Heart Fail; 2009 Jul; 2(4):294-302. PubMed ID: 19808352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure.
    Arimoto T; Takeishi Y; Niizeki T; Takabatake N; Okuyama H; Fukui A; Tachibana H; Nozaki N; Hirono O; Tsunoda Y; Miyashita T; Shishido T; Takahashi H; Koyama Y; Kubota I
    J Card Fail; 2005 Oct; 11(8):595-601. PubMed ID: 16230262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure.
    Güder G; Bauersachs J; Frantz S; Weismann D; Allolio B; Ertl G; Angermann CE; Störk S
    Circulation; 2007 Apr; 115(13):1754-61. PubMed ID: 17372171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum cortisol as a useful predictor of cardiac events in patients with chronic heart failure: the impact of oxidative stress.
    Yamaji M; Tsutamoto T; Kawahara C; Nishiyama K; Yamamoto T; Fujii M; Horie M
    Circ Heart Fail; 2009 Nov; 2(6):608-15. PubMed ID: 19919986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality.
    Ceconi C; Ferrari R; Bachetti T; Opasich C; Volterrani M; Colombo B; Parrinello G; Corti A
    Eur Heart J; 2002 Jun; 23(12):967-74. PubMed ID: 12069452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure.
    Suzuki S; Takeishi Y; Niizeki T; Koyama Y; Kitahara T; Sasaki T; Sagara M; Kubota I
    Am Heart J; 2008 Jan; 155(1):75-81. PubMed ID: 18082493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time.
    Miller WL; Hartman KA; Burritt MF; Grill DE; Rodeheffer RJ; Burnett JC; Jaffe AS
    Circulation; 2007 Jul; 116(3):249-57. PubMed ID: 17592074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and prognostic value of Duke's Activity Status Index along with plasma B-type natriuretic peptide levels in chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
    Parissis JT; Nikolaou M; Birmpa D; Farmakis D; Paraskevaidis I; Bistola V; Katsoulas T; Filippatos G; Kremastinos DT
    Am J Cardiol; 2009 Jan; 103(1):73-5. PubMed ID: 19101233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline and 6-month B-type natriuretic peptide changes are independent predictors of events in patients with advanced heart failure awaiting cardiac transplantation.
    Campana C; Pasotti M; Klersy C; Alessandrino G; Albertini R; Magrini G; Ghio S; Tavazzi L
    J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):671-6. PubMed ID: 19444135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure.
    Latini R; Masson S; Anand IS; Missov E; Carlson M; Vago T; Angelici L; Barlera S; Parrinello G; Maggioni AP; Tognoni G; Cohn JN;
    Circulation; 2007 Sep; 116(11):1242-9. PubMed ID: 17698733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-blockers influence the short-term and long-term prognostic information of natriuretic peptides and catecholamines in chronic heart failure independent from specific agents.
    Frankenstein L; Nelles M; Slavutsky M; Schellberg D; Doesch A; Katus H; Remppis A; Zugck C
    J Heart Lung Transplant; 2007 Oct; 26(10):1033-9. PubMed ID: 17919624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial.
    Staszewsky L; Wong M; Masson S; Barlera S; Carretta E; Maggioni AP; Anand IS; Cohn JN; Tognoni G; Latini R;
    J Card Fail; 2007 Dec; 13(10):797-804. PubMed ID: 18068611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of exercise capacity improvement after exercise training program: a strong prognostic factor in patients with chronic heart failure.
    Tabet JY; Meurin P; Beauvais F; Weber H; Renaud N; Thabut G; Cohen-Solal A; Logeart D; Ben Driss A
    Circ Heart Fail; 2008 Nov; 1(4):220-6. PubMed ID: 19808295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors.
    Güder G; Frantz S; Bauersachs J; Allolio B; Wanner C; Koller MT; Ertl G; Angermann CE; Störk S
    Circ Heart Fail; 2009 Nov; 2(6):563-71. PubMed ID: 19919981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.
    Milting H; Ellinghaus P; Seewald M; Cakar H; Bohms B; Kassner A; Körfer R; Klein M; Krahn T; Kruska L; El Banayosy A; Kramer F
    J Heart Lung Transplant; 2008 Jun; 27(6):589-96. PubMed ID: 18503956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy.
    Theodoropoulos TA; Bestetti RB; Otaviano AP; Cordeiro JA; Rodrigues VC; Silva AC
    Int J Cardiol; 2008 Aug; 128(1):22-9. PubMed ID: 18258318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.